日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma

贝伐珠单抗和厄洛替尼作为晚期肝细胞癌二线疗法的II期临床试验

期刊:Oncotargets and Therapy
影响因子:2.8
doi:10.2147/OTT.S91977
Kaseb, Ahmed O; Morris, Jeffrey S; Iwasaki, Michiko; Al-Shamsi, Humaid O; Raghav, Kanwal Pratap Singh; Girard, Lauren; Cheung, Sheree; Nguyen, Van; Elsayes, Khaled M; Xiao, Lianchun; Abdel-Wahab, Reham; Shalaby, Ahmed S; Hassan, Manal; Hassabo, Hesham M; Wolff, Robert A; Yao, James C
细胞生物学
肿瘤
肿瘤免疫
发表日期：2016
文献求助 收藏

Validation of an IGF-CTP scoring system for assessing hepatic reserve in Egyptian patients with hepatocellular carcinoma.

验证IGF-CTP评分系统在评估埃及肝细胞癌患者肝脏储备功能中的应用

期刊:Oncotarget
影响因子:
doi:10.18632/oncotarget.4176
Abdel-Wahab Reham, Shehata Samir, Hassan Manal M, Xiao Lianchun, Lee Ju-Seog, Cheung Sheree, Essa Hoda H, Hassabo Hesham M, Shalaby Ahmed S, Mosad Eman, Raghav Kanwal, Rashid Asif, Wolff Robert A, Morris Jeffrey S, Amin Hesham M, Kaseb Ahmed O
细胞生物学
肿瘤免疫
发表日期：2015
文献求助 收藏

Development and validation of insulin-like growth factor-1 score to assess hepatic reserve in hepatocellular carcinoma.

开发和验证胰岛素样生长因子-1评分以评估肝细胞癌的肝脏储备

期刊:Jnci-Journal of the National Cancer Institute
影响因子:7.2
doi:10.1093/jnci/dju088
Kaseb Ahmed O, Xiao Lianchun, Hassan Manal M, Chae Young Kwang, Lee Ju-Seog, Vauthey Jean-Nicolas, Krishnan Sunil, Cheung Sheree, Hassabo Hesham M, Aloia Thomas, Conrad Claudius, Curley Steven A, Vierling John M, Jalal Prasun, Raghav Kanwal, Wallace Michael, Rashid Asif, Abbruzzese James L, Wolff Robert A, Morris Jeffrey S
细胞生物学
肿瘤免疫
发表日期：2014
文献求助 收藏